Literature DB >> 17258906

BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice.

Masuo Ohno1, Sarah L Cole, Marina Yasvoina, Jie Zhao, Martin Citron, Robert Berry, John F Disterhoft, Robert Vassar.   

Abstract

Evidence suggests that beta-amyloid (Abeta) peptide triggers a pathogenic cascade leading to neuronal loss in Alzheimer's disease (AD). However, the causal link between Abeta and neuron death in vivo remains unclear since most animal models fail to recapitulate the dramatic cell loss observed in AD. We have recently developed transgenic mice that overexpress human APP and PS1 with five familial AD mutations (5XFAD mice) and exhibit robust neuron death. Here, we demonstrate that genetic deletion of the beta-secretase (BACE1) not only abrogates Abeta generation and blocks amyloid deposition but also prevents neuron loss found in the cerebral cortex and subiculum, brain regions manifesting the most severe amyloidosis in 5XFAD mice. Importantly, BACE1 gene deletion also rescues memory deficits in 5XFAD mice. Our findings provide strong evidence that Abeta ultimately is responsible for neuron death in AD and validate the therapeutic potential of BACE1-inhibiting approaches for the treatment of AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17258906      PMCID: PMC1876698          DOI: 10.1016/j.nbd.2006.12.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  75 in total

1.  BACE1 is the major beta-secretase for generation of Abeta peptides by neurons.

Authors:  H Cai; Y Wang; D McCarthy; H Wen; D R Borchelt; D L Price; P C Wong
Journal:  Nat Neurosci       Date:  2001-03       Impact factor: 24.884

2.  Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.

Authors:  Y Luo; B Bolon; S Kahn; B D Bennett; S Babu-Khan; P Denis; W Fan; H Kha; J Zhang; Y Gong; L Martin; J C Louis; Q Yan; W G Richards; M Citron; R Vassar
Journal:  Nat Neurosci       Date:  2001-03       Impact factor: 24.884

3.  Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase.

Authors:  S Kitazume; Y Tachida; R Oka; K Shirotani; T C Saido; Y Hashimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

4.  Identification of a novel aspartic protease (Asp 2) as beta-secretase.

Authors:  I Hussain; D Powell; D R Howlett; D G Tew; T D Meek; C Chapman; I S Gloger; K E Murphy; C D Southan; D M Ryan; T S Smith; D L Simmons; F S Walsh; C Dingwall; G Christie
Journal:  Mol Cell Neurosci       Date:  1999-12       Impact factor: 4.314

Review 5.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

6.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.

Authors:  S L Roberds; J Anderson; G Basi; M J Bienkowski; D G Branstetter; K S Chen; S B Freedman; N L Frigon; D Games; K Hu; K Johnson-Wood; K E Kappenman; T T Kawabe; I Kola; R Kuehn; M Lee; W Liu; R Motter; N F Nichols; M Power; D W Robertson; D Schenk; M Schoor; G M Shopp; M E Shuck; S Sinha; K A Svensson; G Tatsuno; H Tintrup; J Wijsman; S Wright; L McConlogue
Journal:  Hum Mol Genet       Date:  2001-06-01       Impact factor: 6.150

Review 7.  Transgenic mouse models of Alzheimer's disease.

Authors:  C Janus; D Westaway
Journal:  Physiol Behav       Date:  2001-08

8.  APP processing and synaptic plasticity in presenilin-1 conditional knockout mice.

Authors:  H Yu; C A Saura; S Y Choi; L D Sun; X Yang; M Handler; T Kawarabayashi; L Younkin; B Fedeles; M A Wilson; S Younkin; E R Kandel; A Kirkwood; J Shen
Journal:  Neuron       Date:  2001-09-13       Impact factor: 17.173

9.  Memory impairment and cholinergic dysfunction by centrally administered Abeta and carboxyl-terminal fragment of Alzheimer's APP in mice.

Authors:  S H Choi; C H Park; J W Koo; J H Seo; H S Kim; S J Jeong; J H Lee; S S Kim; Y H Suh
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

10.  Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties.

Authors:  M Haniu; P Denis; Y Young; E A Mendiaz; J Fuller; J O Hui; B D Bennett; S Kahn; S Ross; T Burgess; V Katta; G Rogers; R Vassar; M Citron
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

View more
  133 in total

Review 1.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

2.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

3.  Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice.

Authors:  Latha Devi; Masuo Ohno
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

4.  Synaptic deficits are rescued in the p25/Cdk5 model of neurodegeneration by the reduction of β-secretase (BACE1).

Authors:  Paola Giusti-Rodríguez; Jun Gao; Johannes Gräff; Damien Rei; Takahiro Soda; Li-Huei Tsai
Journal:  J Neurosci       Date:  2011-11-02       Impact factor: 6.167

5.  A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Hiroaki Fukumoto; Hideki Takahashi; Naoki Tarui; Junji Matsui; Taisuke Tomita; Mitsuhiro Hirode; Masumi Sagayama; Ryouta Maeda; Makiko Kawamoto; Kazuko Hirai; Jun Terauchi; Yasufumi Sakura; Mitsuru Kakihana; Kaneyoshi Kato; Takeshi Iwatsubo; Masaomi Miyamoto
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

6.  Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice as a Model of Alzheimer's Disease.

Authors:  Brian M Kopec; Liqin Zhao; Eduardo Rosa-Molinar; Teruna J Siahaan
Journal:  Med Res Arch       Date:  2020-02

7.  Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.

Authors:  L Devi; M Ohno
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 8.  Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases.

Authors:  Rutao Liu; Jing Liu; Xiaofei Ji; Yang Liu
Journal:  Metab Brain Dis       Date:  2013-12       Impact factor: 3.584

Review 9.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 10.  Targeting the β secretase BACE1 for Alzheimer's disease therapy.

Authors:  Riqiang Yan; Robert Vassar
Journal:  Lancet Neurol       Date:  2014-02-17       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.